Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + bortezomib + dexamethasone in relapsed or relapsed/refractory multiple myeloma
2015-005105-36Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Pharmacyclics. Primary endpoint: Median progression-free survival. Started Mar 2016; status: completed.
02
Drugs
ibrutinibbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2015-005105-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005105-36.